Relay Therapeutics Secures $159M from ATM Offering, Extends Cash Runway into 2029
RLAY has more than doubled off its 52-week low of $2.67.
Summary
Relay Therapeutics reported a significant increase in cash reserves to $642.1 million, extending its cash runway into 2029, driven by $137.1 million in net proceeds from an ATM offering in Q1 2026 and an additional $22.1 million in April 2026.
Key Events · Financing and Capital Events · RLAY
-
Significant Capital Raise
The company generated $137.1 million in net proceeds from its At-The-Market (ATM) offering during the first quarter of 2026, with an additional $22.1 million in net proceeds in April 2026, totaling $159.2 million.
-
Strengthened Cash Position and Runway
Cash, cash equivalents, and investments increased to $642.1 million as of March 31, 2026, which is expected to fund operations into 2029.
-
Improved Financial Performance
Net loss decreased to $73.3 million in Q1 2026 from $77.1 million in Q1 2025, and total operating expenses decreased by $10.9 million year-over-year.
-
Continued Clinical Progress
The company continues to advance its lead product candidate, zovegalisib, which recently received FDA Breakthrough Therapy designation, and other pipeline programs.
Analysis · RLAY · Life Sciences
This quarterly report highlights a significant strengthening of Relay Therapeutics' financial position, primarily through a substantial capital raise via its At-The-Market (ATM) offering. The $137.1 million in net proceeds during Q1 2026, supplemented by an additional $22.1 million in April 2026, has boosted the company's cash reserves to $642.1 million and reaffirmed its cash runway into 2029. This capital infusion, coupled with reduced net losses and operating expenses, is crucial for a clinical-stage biotech, enabling continued development of its pipeline, including the recently designated Breakthrough Therapy candidate, zovegalisib. While the ATM offering introduces dilution, the enhanced financial stability significantly de-risks the company's operational outlook and ability to fund its strategic initiatives.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $12.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $2.67 to $17.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.